<p>Korro Bio（纳斯达克代码：KRRO - 获取免费报告）于周三发布了季度财报。该公司报告每股收益（EPS）为（$1.92），超出分析师一致预期的（$2.61）$0.69，Zacks 报道。</p>
<h2>Korro Bio 股价下跌 4.2%</h2>
<ul>
<li>三只可能因欧洲银行降息而上涨的股票</li>
</ul>
<p>周三午盘交易中，Korro Bio 股票下跌 $1.38，报 $31.42。该公司的交易量为 1,634,378 股，而其平均交易量为 190,818 股。该公司的 50 日简单移动平均线为 $38.69，200 日简单移动平均线为 $23.58。Korro Bio 的一年低点为 $10.29，一年高点为 $70.49。</p>
<h2>分析师评级上调与下调</h2>
<p>几位研究分析师最近对 KRRO 股票发表了看法。Raymond James Financial 将 Korro Bio 的目标价从 $153.00 下调至 $147.00，并在 8 月 13 日的研究报告中给予该股票 &#34;强力买入&#34; 评级。HC Wainwright 将 Korro Bio 的目标价从 $100.00 下调至 $90.00，并在 8 月 13 日的报告中给予该股票 &#34;买入&#34; 评级。Weiss Ratings 在 10 月 14 日的研究报告中重新发布了对 Korro Bio 股票的 &#34;卖出（d-）&#34; 评级。最后，Chardan Capital 在 8 月 13 日的研究报告中重申了 &#34;买入&#34; 评级，并对 Korro Bio 股票设定了 $25.00 的目标价。两位投资分析师给予该股票 &#34;强力买入&#34; 评级，五位给予 &#34;买入&#34; 评级，一位给予 &#34;卖出&#34; 评级。根据 MarketBeat.com 的数据，Korro Bio 的一致评级为 &#34;买入&#34;，一致目标价为 $86.83。</p>
<p><strong>查看我们最新的 KRRO 研究报告</strong></p>
<h2>对 Korro Bio 的对冲基金看法</h2>
<p>对冲基金最近调整了对该股票的持有。Vanguard Group Inc. 在第三季度将其在 Korro Bio 的持股增加了 2.3%。Vanguard Group Inc. 目前拥有 395,659 股该公司的股票，价值 $18,948,000，此前在上个季度购买了额外的 8,921 股。Geode Capital Management LLC 在第二季度将其在 Korro Bio 的持股增加了 10.8%。Geode Capital Management LLC 目前拥有 155,387 股该公司的股票，价值 $1,941,000，此前在上个季度购买了额外的 15,166 股。Raymond James Financial Inc. 在第二季度将其在 Korro Bio 的持股增加了 357.6%。Raymond James Financial Inc. 目前拥有 83,392 股该公司的股票，价值 $1,042,000，此前在上个季度购买了额外的 65,170 股。最后，Bank of America Corp DE 在第二季度将其在 Korro Bio 的持股增加了 520.0%。Bank of America Corp DE 目前拥有 28,156 股该公司的股票，价值 $352,000，此前在上个季度购买了额外的 23,615 股。13.18% 的股票由机构投资者和对冲基金持有。</p>
<h2>Korro Bio 公司简介</h2>
<p>（获取免费报告）</p>
<p>Korro Bio, Inc. 是一家生物制药公司，专注于基于 RNA 编辑的基因药物的发现、开发和商业化，主要用于治疗稀有和高度流行的疾病，主要在美国。其主要产品候选药物是 KRRO-110，目前正在进行 Alpha-1 抗胰蛋白酶缺乏症（AATD）的临床前试验。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票而非 Korro Bio</li>
<li>消费者物价指数测量什么？</li>
<li>稀土股票：并非真正的休战</li>
<li>什么是债券市场假期？如何投资和交易</li>
<li>切分利润：感恩节餐桌上的三只食品股票</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投资股票</li>
<li>C3.ai 的重置：为何新领导层可能引发转机</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1JSTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1JSTw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Korro Bio 吗？</h2>
<p>在你考虑投资 Korro Bio 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Korro Bio 并不在名单上。</p>
<p>虽然 Korro Bio 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

KRRO

<p>Korro Bio（纳斯达克代码：KRRO）报告的季度每股收益为（$1.92），超出市场共识预期的（$2.61）$0.69。尽管出现了积极的盈利意外，股价仍下跌 4.2%，至$31.42。分析师的评级意见不一，市场共识为 “买入”，目标价为$86.83。对冲基金已调整其持仓，Vanguard 和 Geode Capital 的持仓显著增加。Korro Bio 专注于基因药物，其主要产品 KRRO-110 正在进行针对α-1 抗胰蛋白酶缺乏症的临床前试验</p>

<p>Korro Bio (NASDAQ:KRRO - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($1.92) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.61) by $0.69, Zacks reports.</p>
<div class="lb-trans"><p>Korro Bio（纳斯达克代码：KRRO - 获取免费报告）于周三发布了季度财报。该公司报告每股收益（EPS）为（$1.92），超出分析师一致预期的（$2.61）$0.69，Zacks 报道。</p>
</div><h2>Korro Bio Trading Down 4.2%</h2>
<div class="lb-trans"><h2>Korro Bio 股价下跌 4.2%</h2>
</div><ul>
<li>3 Stocks That Could Rise on European Bank Interest Rate Cuts</li>
</ul>
<div class="lb-trans"><ul>
<li>三只可能因欧洲银行降息而上涨的股票</li>
</ul>
</div><p>Shares of Korro Bio stock traded down $1.38 during midday trading on Wednesday, hitting $31.42. The company had a trading volume of 1,634,378 shares, compared to its average volume of 190,818. The business's 50 day simple moving average is $38.69 and its two-hundred day simple moving average is $23.58. Korro Bio has a 1-year low of $10.29 and a 1-year high of $70.49.</p>
<div class="lb-trans"><p>周三午盘交易中，Korro Bio 股票下跌 $1.38，报 $31.42。该公司的交易量为 1,634,378 股，而其平均交易量为 190,818 股。该公司的 50 日简单移动平均线为 $38.69，200 日简单移动平均线为 $23.58。Korro Bio 的一年低点为 $10.29，一年高点为 $70.49。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>Several research analysts recently weighed in on KRRO shares. Raymond James Financial dropped their price target on Korro Bio from $153.00 to $147.00 and set a &#34;strong-buy&#34; rating on the stock in a research report on Wednesday, August 13th. HC Wainwright dropped their target price on Korro Bio from $100.00 to $90.00 and set a &#34;buy&#34; rating on the stock in a report on Wednesday, August 13th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Korro Bio in a research report on Tuesday, October 14th. Finally, Chardan Capital reiterated a &#34;buy&#34; rating and issued a $25.00 price objective on shares of Korro Bio in a research note on Wednesday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Korro Bio has a consensus rating of &#34;Buy&#34; and a consensus price target of $86.83.</p>
<div class="lb-trans"><p>几位研究分析师最近对 KRRO 股票发表了看法。Raymond James Financial 将 Korro Bio 的目标价从 $153.00 下调至 $147.00，并在 8 月 13 日的研究报告中给予该股票 &#34;强力买入&#34; 评级。HC Wainwright 将 Korro Bio 的目标价从 $100.00 下调至 $90.00，并在 8 月 13 日的报告中给予该股票 &#34;买入&#34; 评级。Weiss Ratings 在 10 月 14 日的研究报告中重新发布了对 Korro Bio 股票的 &#34;卖出（d-）&#34; 评级。最后，Chardan Capital 在 8 月 13 日的研究报告中重申了 &#34;买入&#34; 评级，并对 Korro Bio 股票设定了 $25.00 的目标价。两位投资分析师给予该股票 &#34;强力买入&#34; 评级，五位给予 &#34;买入&#34; 评级，一位给予 &#34;卖出&#34; 评级。根据 MarketBeat.com 的数据，Korro Bio 的一致评级为 &#34;买入&#34;，一致目标价为 $86.83。</p>
</div><p><strong>View Our Latest Research Report on KRRO</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 KRRO 研究报告</strong></p>
</div><h2>Hedge Funds Weigh In On Korro Bio</h2>
<div class="lb-trans"><h2>对 Korro Bio 的对冲基金看法</h2>
</div><p>Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of Korro Bio by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 395,659 shares of the company's stock worth $18,948,000 after purchasing an additional 8,921 shares during the last quarter. Geode Capital Management LLC boosted its position in Korro Bio by 10.8% in the second quarter. Geode Capital Management LLC now owns 155,387 shares of the company's stock valued at $1,941,000 after buying an additional 15,166 shares in the last quarter. Raymond James Financial Inc. grew its stake in Korro Bio by 357.6% during the second quarter. Raymond James Financial Inc. now owns 83,392 shares of the company's stock worth $1,042,000 after buying an additional 65,170 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Korro Bio by 520.0% during the second quarter. Bank of America Corp DE now owns 28,156 shares of the company's stock worth $352,000 after buying an additional 23,615 shares in the last quarter. 13.18% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>对冲基金最近调整了对该股票的持有。Vanguard Group Inc. 在第三季度将其在 Korro Bio 的持股增加了 2.3%。Vanguard Group Inc. 目前拥有 395,659 股该公司的股票，价值 $18,948,000，此前在上个季度购买了额外的 8,921 股。Geode Capital Management LLC 在第二季度将其在 Korro Bio 的持股增加了 10.8%。Geode Capital Management LLC 目前拥有 155,387 股该公司的股票，价值 $1,941,000，此前在上个季度购买了额外的 15,166 股。Raymond James Financial Inc. 在第二季度将其在 Korro Bio 的持股增加了 357.6%。Raymond James Financial Inc. 目前拥有 83,392 股该公司的股票，价值 $1,042,000，此前在上个季度购买了额外的 65,170 股。最后，Bank of America Corp DE 在第二季度将其在 Korro Bio 的持股增加了 520.0%。Bank of America Corp DE 目前拥有 28,156 股该公司的股票，价值 $352,000，此前在上个季度购买了额外的 23,615 股。13.18% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Korro Bio Company Profile</h2>
<div class="lb-trans"><h2>Korro Bio 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).</p>
<div class="lb-trans"><p>Korro Bio, Inc. 是一家生物制药公司，专注于基于 RNA 编辑的基因药物的发现、开发和商业化，主要用于治疗稀有和高度流行的疾病，主要在美国。其主要产品候选药物是 KRRO-110，目前正在进行 Alpha-1 抗胰蛋白酶缺乏症（AATD）的临床前试验。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Korro Bio</li>
<li>What does consumer price index measure?</li>
<li>Rare Earth Stocks: The Truce That Isn't a Truce</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>Carving Up Profits: 3 Food Stocks on the Thanksgiving Table</li>
<li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li>
<li>C3.ai's Reset: Why New Leadership Could Spark a Turnaround</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票而非 Korro Bio</li>
<li>消费者物价指数测量什么？</li>
<li>稀土股票：并非真正的休战</li>
<li>什么是债券市场假期？如何投资和交易</li>
<li>切分利润：感恩节餐桌上的三只食品股票</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投资股票</li>
<li>C3.ai 的重置：为何新领导层可能引发转机</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1JSTw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=KRRO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Korro Bio Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Korro Bio 吗？</h2>
</div><p>Before you consider Korro Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Korro Bio 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Korro Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Korro Bio 并不在名单上。</p>
</div><p>While Korro Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Korro Bio 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Korro Bio（纳斯达克股票代码：KRRO）公布财报，每股收益超出预期 0.69 美元